Clinical Efficacy Of Hematopoietic Stem Cell Transplantation In Hematologic Malignancies

There is clinical evidence that syngeneic, autologous, and allogeneic HSCT all provide benefit, defined as response, freedom of progression, or overall survival, for the majority of hematologic malignancies.3 However, the beneficial effects of these various forms of HSCT vary greatly with each hematologic malignancy. Myeloablative conditioning regimens with syngeneic, autologous, or allogeneic HSCT result in higher response rates than conventional cytotoxic agents for almost all hematologic malignancies. However, the durability of these responses and their effect on survival varies from disease to disease. Similarly, there is evidence of a clinical GVL effect in almost every hematologic disease; however, the potency and clinical relevance is highly variable. This section will briefly cover the susceptibility of hematologic malignancies to the different forms and effects of HSCT.

0 0

Post a comment